How did Reveleum’s experience in the NEC X Elev X! Ignite Venture Studio Program impact the company’s strategic direction and growth trajectory?
NEC X’s Elev X! played a pivotal role in helping us bring our software to market. One of the most impactful lessons we learned was a fundamental yet crucial question: What problem are you solving, and does it truly need to be solved? While many great ideas exist, it’s essential to assess how much of a priority the problem is for customers compared to other challenges they face daily.

Elev X! guided us through this process by encouraging us to conduct hundreds of customer interviews. They also taught us how to ask unbiased, non-leading questions—helping us avoid the trap of seeking validation for our pre-existing solution. This experience fundamentally shaped our approach to product development and market fit, ensuring we address real, pressing customer needs.

What were the key milestones and challenges Reveleum faced during the development of its proprietary technology for medical record management?
Our first major milestone was customer discovery. We conducted over 30 phone and Zoom interviews with healthcare professionals, followed by on-site observations to see their workflows in action—a practice we continue today. Interviews often present idealized or worst-case scenarios, but direct observation provided deeper insights into real challenges. This hands-on approach allowed us to develop a solution that truly addressed the problem.

One of our biggest challenges was securing time with customers—not only for discussions but also for live testing. Overcoming this hurdle led to our most significant milestone: successfully conducting beta testing in a live healthcare environment.

How does Reveleum differentiate itself from other health tech startups focusing on medical record management and operational efficiency?
Reveleum stands out due to our deep expertise in both LEAN methodologies and healthcare operations. While most software solutions automate manual tasks, we took a different approach. We first defined the core problem, then applied a LEAN methodology to seamlessly integrate into existing workflows without disruption.

Additionally, we prioritized data security, designing our platform to meet the same stringent standards as internal hospital networks. Finally, our irresistible pricing model offers a competitive advantage, making our solution both cost-effective and highly valuable.

Can you discuss any specific strategies Reveleum has employed to secure investment and support from NEC X?
Our initial funding came from angel investors, many of whom were close connections or referrals. We presented them with our vision for improving healthcare, backed by a strong business case. When considering venture studio and accelerator programs, we were drawn to NEC X for its deep technology expertise, strong corporate backing and ability to provide more than just funding. NEC X’s hands-on collaboration, access to NEC’s research and LLM technology and opportunities for strategic partnerships aligned with our goals.

The NEC X application process was straightforward. We applied online and were evaluated on innovation, market potential, scalability and alignment with NEC X’s focus. I encourage others with a clear vision and the potential for market impact to apply with NEC X.

How has Reveleum’s platform demonstrated its value in improving operational efficiency and patient outcomes for healthcare providers?
From the start, our platform was designed to enhance both operational efficiency and patient outcomes. It enables clinicians to quickly access critical data that is often buried in traditional EMRs.

However, what truly set us apart was our commitment to flexibility and continuous customer feedback. By listening to our early users, we developed additional features that directly impact revenue generation and cost reduction. Our clients have reported increased throughput, Improved clinician satisfaction with EMR navigation and direct revenue gains through enhanced reporting.

What are the major pain points in healthcare record management that Reveleum aims to address, and how does its technology solve these issues?
Currently, external medical records are shared via read-only portals (e.g., Care Everywhere, MyChart) or electronic fax (e-fax). While these documents can be imported into EMRs, they lack searchability and structured indexing. Reveleum solves this by:

• Automatically indexing documents by category (e.g., Labs, Radiology, OP Reports).
  
• Creating a keyword-based table of contents for each record.
  
• Using EMR-standard terminology for easy integration.
  
• Automate the entire process upon document receipt.

This ensures clinicians can quickly locate and access relevant information without manual sorting or searching.

How does Reveleum plan to scale its operations and expand its market presence in the coming years?
Initially, we focused on community-based hospitals (<200 beds) due to their simpler decision-making structures. We are gaining traction through word-of-mouth referrals among similar-sized hospitals. Additionally, we have:

• Engaged hospital executives to discuss our impact with potential clients.
• Begun procurement processes with two large hospital networks.
• Planned entry into industry trade shows upon securing larger clients.
• Hired our first salesperson, with plans to expand nationally as traction grows.

What advice would you give to other health tech startups looking to secure investment and partnership opportunities similar to those provided by NEC X?
My biggest takeaway from participating in an incubator program like NEC X was the importance of preparation. We had pre-work assignments before attending the intensive week in Palo Alto, and the more prepared we were, the more we benefited.

Out of 150 applicants, only 6 were selected as finalists and just three received funding. Success required excelling in their structured nine-month program, but the dedication paid off. Not only did we secure funding, but NEC X’s support helped us attract additional investors.

We’ve maintained weekly advisory meetings with NEC X since our acceptance, leveraging their expertise for ongoing guidance and strategy. Their mentorship has been invaluable in shaping our growth.

The post Reveleum revolutionizes healthcare with NEC X support appeared first on My Startup World - Everything About the World of Startups!.

Hilbi isn’t just another healthcare tech company – it’s a patient-centric revolution in digital patient management, where patients are treated as clients. By seamlessly integrating transactional management, electronic health records (EHR), and AI-driven analytics, Hilbi has created a unique, borderless ecosystem that synchronizes healthcare data with the client at the center. This innovative approach enhances decision-making, streamlines workflows, and uncovers new revenue opportunities for healthcare providers. Hilbi is setting a new standard for the future of digital healthcare.

Hilbi’s innovation is already transforming healthcare delivery. Current data shows that hospitals and clinics using Hilbi experience a 20% increase in workflow efficiency, while providers see a revenue boost of up to 35% – a game-changer in an industry under constant financial and operational pressure.

“At Hilbi, we are not just building technology, we are redefining how healthcare operates. Our platform seamlessly integrates with existing systems, empowering medical professionals with the tools they need to provide better care while optimizing their business. The numbers speak for themselves – Hilbi is making a real difference,” said Roman Kučera, Co-founder / CTO.

Patrik Kmeč, Co-founder / CEO, added: “This investment represents an important step for Hilbi as we work towards expanding globally. Our mission has always been to improve healthcare by making it more accessible and patient-centered. Ishtar’s expertise in emerging markets aligns well with Hilbi’s growth strategy. It’s not just about expansion; we’re laying the groundwork for a global digital health infrastructure. With Ishtar’s international reach and connections in key financial hubs, we are in a stronger position to establish a presence in multiple regions. Together, we hope to move closer to our goal of transforming digital healthcare on a larger scale.”

Hilbi is rolling out its technology in India, a rapidly growing healthcare economy, to digitize patient management, data analytics, and healthcare transactions – unlocking a billion-dollar market.

Among the first adopters is DPU Super Specialty Hospital, one of India’s most prestigious and forward-thinking medical institutions. With 1,000+ experienced doctors and more than 2,000 beds, DPU is pioneering AI-driven healthcare innovation and setting new benchmarks for efficiency, patient care, and digital transformation.

“Hilbi paves the way for seamless integration of digital medical tools into clinical practice. Our doctors love Hilbi’s native interface, and I’m excited that this technology is taking our vision of becoming a leader in healthcare management innovation to new heights. This collaboration will set new standards in healthcare – not just for us, but for the entire Indian healthcare ecosystem,” said Dr. Yashraj Patil, Trustee, DPU Super Specialty Hospital, Pune, India.

Already transforming clinics, hospitals, and university medical centers across Eastern Europe, and now with the establishment of its subsidiary in India, Hilbi is accelerating global expansion into one of the world’s fastest-growing markets. This strategic move strengthens partnerships with local providers, optimizes patient care, and drives innovation in regions with the highest demand for digital health solutions.

The post Hilbi secures €8 million investment from Ishtar Advisory appeared first on My Startup World - Everything About the World of Startups!.

The acquisition coincides with a strategic funding round led by Beltone Venture Capital and Raed Ventures, securing Grinta undisclosed capital to further its growth.

Grinta’s Co-founder and CEO, Mohamed Azab, emphasized the transformative nature of the acquisition: “This step allows us to integrate offline and online services, reshaping how healthcare is accessed and delivered. It’s a significant leap into the care market, setting the stage for broader impact.”

This aligns with a global trend where B2B pharmaceutical distributors are shifting toward consumer-focused healthcare services. Inspired by industry models like McKesson and Walgreens, Grinta is now focusing on expanding both physical and digital healthcare services in Egypt and East Africa.

In tandem with this new direction, Grinta has exited its B2B retail pharmaceutical distribution business in Egypt, signaling its full commitment to the care sector.

Ali Mokhtar, Managing Director of Beltone Venture Capital, highlighted the strategic vision: “This shift reflects Grinta’s ability to adapt and thrive, positioning itself as a regional healthcare leader.”

Wael Nafee of Raed Ventures expressed confidence in Grinta’s innovation-driven approach: “We’re excited to support their ambitious plans to improve healthcare access across emerging markets.”

In East Africa, Grinta’s expansion strategy includes exporting pharmaceutical products, forging partnerships with Egyptian manufacturers, and establishing a pharmacy chain in Tanzania using a buy-and-build model.

With these advancements, Grinta is charting a bold course in reshaping healthcare in emerging markets. Its entry into primary care represents a meaningful shift toward patient-centric solutions and a mission to ensure better healthcare access for all.

The post Grinta acquires Citi Clinic to expand its footprint appeared first on My Startup World - Everything About the World of Startups!.

What’s more, the U.S. healthcare system averages $1 trillion in administrative spending annually, representing roughly 20% to 30% of total healthcare expenditure in the country.

But the days of wasteful expenditures, overworked staff, and suboptimal patient care may soon be coming to an end. As fate would have it, healthcare institutions stand to be major beneficiaries of agentic AI, as it can be the transformative tool used to completely rewire their industry. Take these three different healthcare trailblazers, for example, who are using Agentforce — the agentic layer of the Salesforce Platform — ‌to reimagine the future of the healthcare industry with digital labour.

Transcend works to reimagine telehealth
An innovator in the wellness industry, Transcend provides telehealth diagnostics and treatment plans to support health and fitness goals. They target root causes with scientific solutions that are customized to individual patient needs.

As demand for remote health grew, especially over the pandemic, ‌Transcend experienced a surge in client enrollment. Service reps found themselves multitasking far too often — handling orders, inputting data, and navigating multiple platforms to retrieve client information from various systems. The patient spike also took away from the white-glove approach they were accustomed to providing. The provider quickly decided it needed a new, technology-driven approach to its operations and care.

• The Agentforce benefit: With Agentforce, Transcend will be able to meet demand 24/7 support with a limitless digital workforce. Its new agent-first approach will help its medical care clients start care immediately and keep up with it easily. Patients will be able to get immediate answers around a new treatment instead of waiting weeks to get a question answered in an appointment with their practitioner. Agentforce will help Transcend provide a premium, concierge-level experience that their clients expect.
• Taking action: Always-on agents will also help Transcend differentiate itself from competitors by providing convenient customer service. For example, existing clients can immediately search for medication and text Agentforce with any questions as they begin their treatment. Powered by the Atlas Reasoning Engine — the brain behind Agentforce — the AI agent reviews data, surfaces insights, and takes action in real time. Once treatment begins, daily communication with a wellness concierge via SMS is facilitated.

When clients ask about a drug interaction, for example, Agentforce will automatically validate information, such as dosage or lab results, to ensure it meets safety standards. From there, Agentforce will connect them with Transcend’s wellness experts. In the past, this process was done manually and could slow client care. But Agentforce will soon take action on eligibility confirmation, autonomously verifying if a client qualifies for a service or treatment by reasoning across all of this data. With Agentforce, Transcend expects to improve response times by an estimated 30% and support more clients, faster.

“Agentforce will enhance Transcend’s customer support, improving efficiency and making it easier for more people to access treatment,” said Brian Glass, Chief Information Officer of Transcend.

Precina Health dials in on specific treatment
Precina Health is another provider using Agentforce to improve the level of care it’s able to offer, especially for patients with type 2 diabetes. They do this through daily personalized support, targeting lifestyle factors like diet, exercise, and habits to improve outcomes faster.

• The Agentforce benefit: With the prevalence of diagnosed diabetes increasing across all age groups from 2021-2023, Precina needed scalable infrastructure to expand its diabetes care model. With Agentforce, the healthcare provider is now able to automate outreach, scale check-ins, and deliver life-changing care for improved outcomes. Supported by the agentic layer of the Salesforce Platform, Precina revolutionizes how the company delivers diabetes care. And by automating routine tasks and enabling 24/7 support, Agentforce frees providers to focus on high-impact intervention, while saving Precina an estimated $80,000 per year in administrative load.
• Taking action: Instead of a patient waiting months for a clinical visit to adjust a medication dose or review a new dietary habit, Agentforce works behind the scenes, tapping into Salesforce Health Cloud and Data Cloud to instantly access their medical records, lab results, and prescription history. It then uses that data — securely and in compliance with HIPAA standards — to deliver tailored suggestions, recommend incremental lifestyle changes, and even coordinate prescription refills. Agentforce will also expand payer coverage with autonomous outreach and allow Precina to train and coach clinicians faster and more cost-effectively.

A new age of healthcare  
Transcend and Precina Health chose Agentforce as their digital labour platform because it’s deeply integrated with Health Cloud and Data Cloud, a hyperscale data platform built directly into Salesforce that provides access to critical company data and metadata.

Using Agentforce, these healthcare leaders can seamlessly manage key processes from medication checks and pricing approvals to eligibility confirmation and even scheduling, allowing them to focus their attention on providing personalized support where it matters most, driving better outcomes for their patients.

For more on the future of healthcare, discover Agentforce for Health.

The post How Agentic AI to ease healthcare’s workforce crisis appeared first on My Startup World - Everything About the World of Startups!.

The investment, combined with NEC X’s advanced engineering support, will enable Reveleum to scale its proprietary tech solution. The platform is designed to significantly improve operational efficiency, generate revenue, reduce costs and enhance patient outcomes by streamlining workflows and information sharing across healthcare systems with Personal Health Records (PHR).

Reveleum’s platform has shown impressive savings. For a 70-bed rural hospital, Reveleum identified over $250,000 in uncaptured Transitional Care Management (TCM) in its first year of implementation. The solution has also helped hospitals identify and prevent costly 30-day readmissions, reducing revenue losses of $10,000 to $58,000 per case. Nationally, the Centers for Medicare & Medicaid Services (CMS) has reported only 18% of TCM visits were billed.

Hospitals experience an average of 17 readmissions per 100 Medicare discharges. This means larger health systems managing hundreds or thousands of cases could potentially recover millions in lost revenue with Reveleum.

“Reveleum exemplifies the transformative innovation that Elev X! Ignite was designed to support,” said Shintaro Matsumoto, President and CEO of NEC X. “By leveraging advanced technology, Reveleum is addressing one of the healthcare industry’s most critical pain points—ensuring that medical records are not just managed efficiently but also utilized effectively to improve outcomes. This is a groundbreaking leap for operational efficiency and patient care.”

Hospitals and clinics in the U.S. handle an overwhelming volume of medical records daily, much of it reliant on outdated and labor-intensive solutions like e-fax systems.  This manual and error-prone process often leads to missed billing opportunities, administrative delays, duplicated tests and other inefficiencies that cost the healthcare system billions annually.

Due to legacy processes, today’s healthcare leaders face significant challenges in managing administrative workflows. The volume of e-faxes alone can be overwhelming, and many organizations struggle to accurately capture TCM reimbursements. Too often, organizations don’t know what they’re capturing—or what they’re missing.

Reveleum’s platform leverages proprietary technology powered indexing and keyword processing to automatically organize and convert medical records into an easily searchable and scalable digital format. The platform has already demonstrated a significant impact, delivering:

• 80% reduction in staff processing time
• 60% revenue growth in Transitional Care Management (TCM)
• 10% increase in patient visits

“Healthcare providers are burdened by the current inefficiencies of managing medical records, and these challenges often come at the expense of patient care,” said Dr. Sheldon Weiss, CEO and Co-founder of Reveleum. “With NEC X’s investment and expertise, we’re empowering healthcare organizations to break free from outdated processes, enhance revenues, reduce administrative overhead and focus on what matters most—delivering exceptional care.”

The timing of Reveleum’s solution is critical. Regulatory reforms in the U.S. are mandating the standardization and interoperability of medical records, pushing healthcare providers to adopt digital-first solutions like Reveleum to stay compliant and competitive. The opportunity is vast, with the global Electronic Health Records (EHR) market expected to reach USD 43.62 billion by 2032.

To learn more about how Reveleum is setting a new standard for medical record automation, visit https://reveleum.com/.

The post NEC X invests in Reveleum to revolutionize Medical Record Management appeared first on My Startup World - Everything About the World of Startups!.

Since its founding in 2019, Klaim has positioned itself as an innovative and out-of-the-box force in fintech, providing a cutting-edge payment platform specializing in healthcare. Leveraging artificial intelligence and a vast data repository, Klaim predicts insurance payment behaviors through advanced data analytics and AI models. This enables faster and more efficient healthcare claims processing. With the new funds, Klaim aims to expand its footprint in the UAE, deploy capital in Saudi Arabia, Oman, and other regions, and continuously refine its technology to better serve healthcare providers.

Last year, Klaim announced a strategic milestone in its expansion into Saudi Arabia through a collaboration with Tharawat Tuwaiq Financial Company, an asset manager and financial advisor licensed by the Saudi Capital Market Authority (CMA). As part of this collaboration, Tharawat Tuwaiq has successfully obtained approval and launched a healthcare private closed-ended financing fund. The fund, valued at SAR60 million (approximately USD16 million), aims to enhance access to working capital solutions tailored to the healthcare sector’s unique needs. 

The first transaction under this initiative is set to take place in March 2025, further strengthening Klaim’s commitment to empowering healthcare providers with innovative solutions. Additional funds within this program are expected to be introduced in the second half of 2025, reinforcing long-term support for Saudi Arabia’s healthcare ecosystem.

“We’re excited to achieve this milestone in our journey. Securing Series A funding is not only a major validation of our vision and business model but also the critical inflection point that enables us to scale rapidly,” said Karim Dakki, Co-Founder and CEO of Klaim. 

The post Klaim secures $26 million to boost regional growth appeared first on My Startup World - Everything About the World of Startups!.

In recent years, the medical field has witnessed a growing demand for the utilization of RWD/RWE to evaluate the safety and efficacy of drug development and to enhance the efficiency of the development and approval processes. However, several challenges persist in leveraging RWD/RWE, including data collection, standardization of data quality and analytical methods, and regulatory compliance.

Aetion is a global leader in RWE platforms. The Aetion Evidence Platform (AEP) is utilized by numerous organizations worldwide, including pharmaceutical companies, regulatory authorities, insurers, and healthcare institutions. AEP enables the standardization, quality assurance, and transparency of RWD, facilitating rapid and accurate analysis from a wide variety of data sources. Additionally, it transforms RWD using scientifically validated methods to generate reliable RWE. This approach addresses the challenges associated with RWD/RWE utilization and supports effective decision-making.

NEC aims to address medical and healthcare challenges and create new value through its healthcare and life sciences business, including electronic medical records. Aetion has a highly reliable and proven track record in evaluating the efficacy and safety of pharmaceuticals. Synergies between the two companies have the potential to improve the efficiency of the drug development process and the creation of new treatment methods. This investment enables NEC and Aetion to further explore business collaboration in the RWD/RWE business in drug development.

“The NEC Orchestrating Future Fund invests in startups that are pioneering new markets with cutting-edge technologies and innovative business models,” said Shigeki Wada, Corporate Senior Vice President of NEC Corporation. “Aetion’s RWD/RWE-based medical decision support can contribute to the establishment of next-generation healthcare and is in line with our vision of contributing to personalized medicine. Together with Aetion, we will accelerate our efforts to create new social value.”

“As Aetion redefines how healthcare organizations make critical decisions with enterprise-grade technology, this investment from NEC Orchestrating Future Fund demonstrates their vision of how our software can help decision-makers in Japan and beyond,” said Jeremy Rassen, ScD, Chief Executive Officer and Co-founder of Aetion. “We look forward to continued collaboration with NEC, innovating together to meet the global demand for decision-grade solutions that drive measurable change across the healthcare landscape.”

The post NEC Orchestrating Future Fund invests in Aetion appeared first on My Startup World - Everything About the World of Startups!.

i3 is selecting a total of 15 leading startups for this cohort:

• 10 early-stage startups innovating in healthcare delivery or product distribution
• 5 growth-stage startups building the future of pharmacy care

Early-stage startups will receive a $50K grant and growth-stage startups will receive a $225K grant to unlock major partnerships that can expand patient access across the continent. For startups in the cohort,  i3 aims to facilitate at least 150 relationships with key healthcare organizations, worth at least $30M,  which will expand patient access while creating valuable local jobs.

In just two years since its launch, i3 has empowered 60 African health innovators across 16  countries, exceeding expectations with 43% women-led and 20% Francophone-led ventures. The program provided $3M in direct grants, and facilitated 450 strategic connections, resulting in >$11M in contracted partnerships, expanded reach, and nearly 1,000 jobs created—half of which were held by women. i3 is coordinated by Salient Advisory and Solina Center for Research and Development  (SCIDaR).

Dr. Uchenna Igbokwe, CEO, SCIDaR “With the right resources, African-led companies can scale commercially while reaching underserved communities and creating jobs. The i3 program has been able  to prove, in just two years, that an actively engaged network of leading global health institutions and  partners can power African innovators to solve critical African problems in healthcare.”

Oghenetega Iortim, CEO of Figorr, a company that provides end-to-end supply chain tracking technology and an i3 alumni, said, “We partnered with the Nigerian government to track over 200M health products. Through i3 we met with major global customers who were excited to find ways to expand  Figorr’s impact both in Nigeria, and beyond. We’re grateful to i3 for opening these doors.”

Applications for the 3rd cohort are open now until February 28. Interested startups can apply here: innovationsinafrica.com/application. The selected startups will be announced on April 30th. A virtual Q&A  session will be hosted by i3 on February 21st to answer any questions regarding the application process.  i3 is coordinated by Salient Advisory and Solina Center for Research and Development (SCIDaR).  Leading tech hubs CcHUB and Villgro Africa will spearhead cohort selection, alongside a distinguished panel of African experts.

The post i3 calls African healthtech startups to join its 3rd cohort appeared first on My Startup World - Everything About the World of Startups!.

The capital will fund BioSapien’s clinical trials in the UAE – with patient enrolments in Abu Dhabi set to begin imminently (Q2 2025). Proceeds will also be allocated to increase product development and manufacturing, and onboard new talent.

BioSapien’s flagship product – MediChip – is a drug delivery, 3D-printed, slow-release delivery platform attachable to any tissue with minimal systemic side effects.

Local delivery means more of the drug stays in the tumor microenvironment (i.e. where the tumor is located) to aid more efficient oncology – such as downsized tumors, alleviated symptoms and preventing potentially life-altering surgeries. Local delivery also requires less quantities of drugs to be used, while maintaining safety.

Initially, BioSapien is developing its platform for clinical trials in colorectal cancer patients, with scope to branch out to other cancers (pancreatic, lung), and non-cancer indications such as opioids, hormones, biologics, cell and gene therapies.

The global cancer drug delivery market is currently valued at $247 billion, with the global colorectal market at $19 billion – growing at 7.2% CAGR and 4% CAGR respectively – emphasising the extensive markets that need addressing.

Khatija Ali, CEO and Founder of BioSapien, said: “We are delighted to announce our pre-Series A fundraise to accelerate our clinical trials and product development. There is a high unmet need for sustained drug release with minimal side effects in healthcare with over 30% of chemotherapy patients enduring severe side effects, often resulting in reduced or halted treatment.

“Our vision is to provide on-the-go therapy and treating cancer locally. Our innovative technology is well-placed to reduce roadblocks and increase quality of life during treatment and potentially prevent life-altering surgeries. We look forward to working closely with our investors and UAE regulators to progress MediChip and revolutionise cancer treatment.”

The benefits of localized drug delivery are multiple, across different stakeholders. Most importantly, for patients – three solvable challenges are tackled: less treatment roadblocks (such as severe side effects halting treatment); better quality-of-life during intensive chemotherapy schedules; and easing the de facto limits, to date, of surgical success. There is also a decreased need for hospital visits and less exposure to the tedious effects and logistics of systemic therapy.

For pharmaceutical companies and healthcare systems: their pipelines can diversify as difficult to treat conditions can be addressed and previously shelved assets can potentially be activated through the platform; their markets can expand (e.g. to animals, emerging markets, paediatric and geriatric) – boosting margins; drug efficacy is enhanced and becomes safer; while regulatory approvals become faster.

Noor Sweid, Founder and Managing Partner of Global Ventures, commented: “We are excited to lead BioSapien’s pre-Series A fundraise and support Khatija’s team in providing a pioneering and local solution to colorectal cancer. BioSapien’s drug delivery technology utilizes advanced 3D printing and epitomizes cost-effective innovation in a market ripe for new solutions with benefits for multiple stakeholders – including the most important of all – patients.

“With the company’s multiple competitive advantages, and the markets for colorectal and wider cancer treatments, BioSapien is at the forefront of advanced technological solutions to meet global demand.”

Sacha Haider, Partner at Global Ventures, said: “We look forward to supporting BioSapien as it disrupts the healthcare sector via innovation seeded from the region. Through localised delivery and using advanced 3D-printing, the company is providing an alternative to traditional cancer treatment. BioSapien’s patented drug delivery platform – MediChip – increases the bioavailability and retention of the desired medication, meaning less is required. This in turn, has the potential to vastly improve the patient’s treatment journey on a global scale.”

The post BioSapien raises $5.5mln in pre-series a funding led by Global Ventures appeared first on My Startup World - Everything About the World of Startups!.

The infusion of capital will be strategically utilized to enhance customer relationships and expand operations to the Southern and Western parts of the country. It will also be channelised to hire fresh talents and develop state-of-the-art B2B loan onboarding and loan management systems, creating an end-to-end digitised B2B healthcare lending framework.

Founded in 2022 by Shrey Jain and Arpit Jangir, HealthCRED is poised to become India’s first healthcare-focused Small Finance Bank (SFB). The company provides swift, comprehensive, and adaptable financing solutions tailored for the healthcare sector. HealthCRED’s collaborative approach involves partnering with Hospitals, specialised Healthcare Service Providers (HSPs across nephrology, oncology, and diagnostics), Insurers, and Pharmaceutical and Consumable Supply Chain partners to deliver intelligent and efficient financing solutions.

Shrey Jain, Co-Founder & CEO of HealthCRED commented, “With the rapid penetration of health insurance in the post-COVID scenario, there has been an increased working capital management stress for Hospitals and HSPs. The key factor is the delay associated with the realisation of insurance receivables. Our aim is to work towards stabilising their cash flow cycles, through early financing of these delayed receivables. This would help further ensure quality delivery of patient care, thereby enabling improved alignment with SDG Target 3.8 and Universal Healthcare Coverage (UHC)”.

Nitin Sharma, Partner at Antler India said, “The healthcare ecosystem faces a significant working capital gap, particularly impacting small to mid-sized hospitals with limited capital access and claims management capabilities. This gap is expected to widen with increasing health insurance penetration and delayed insurer payments. Banks and NBFCs typically focus on large hospital infrastructural loans, leaving small hospitals underserved. HealthCRED aims to address this by offering working capital finance against cashless insurance receivables., targeting a multi-billion dollar gap. We are thrilled to back Shrey, Arpit, and the HealthCRED team to become a major healthcare lender, addressing various financing needs over time.”

HealthCRED is addressing a burgeoning working capital gap in hospitals and the healthcare supply chain, targeting the needs of India’s rapidly growing USD 300 Billion+ healthcare industry. With ambitious growth targets, the company aims to disburse over USD 1 Billion over the next 5 years through digital means, basis alternate data driven underwriting.

The post Indian startup HealthCRED secures $1.2 Million in seed funding appeared first on My Startup World - Everything About the World of Startups!.